IRADIMED share price today

IRADIMED CORPORATION's share price was $88.58 at the close on 4 November 2026. That is 4.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $77 and $104, and at that close it sat 44% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 13 weeks running.

Over the last 1 year the share price moved +54% while the S&P 500 moved +23%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 7 August 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

IRADIMED CORPORATION paid $0.77 per share over the last four reported quarters. The most recent declaration was $0.20 for Jun 2026. At today's price of $88.58 that is a yield of 0.87%, based on dividends already paid, not a forecast.

A dividend is cash paid out for each share. The 12-month total is the four most recent quarters added together.

IRADIMED is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

IRADIMED CORPORATION earned $5.2 M of net profit in the Jun 2026 quarter, −9.6% on the same quarter a year earlier. Full-year FY25 profit was $22.5 M. Over 4 years profit has grown 24.6% a year on average. That is 25.5% of the quarter's revenue. The same quarter a year earlier earned $5.8 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $22.5 M (+16.9% on the year before).

Why profit moved: revenue changed +0.3% on a year earlier and the margin moved −2.1 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +12.6% and revenue +11.4%. Profit and revenue are moving at about the same pace.

IRADIMED CORPORATION reported $20.5 M of revenue in the Jun 2026 quarter, +0.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 19.0% a year on average. The last full year, FY25, came in at $83.8 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $86.3 M.

FY25 revenue was $83.8 M, +14.4% on the year before.

Recent pace: the last four quarters grew +11.4% on average, against 19.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.2%, against +11.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +11.6%, against +11.2% a year (stabilising).

IRADIMED CORPORATION's operating margin was 31.2% in the Jun 2026 quarter, 2.1 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 23.5% and 31.2%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 23.5% and 31.2%, and FY25's 31.2% is the highest of them.

Why the margin moved: operating margin changed −2.1 percentage points on the year while gross margin changed −4.1 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 109% of IRADIMED CORPORATION's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $24.9 M of operating cash against $22.5 M of profit. After $7.8 M of spending on assets, $17.2 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

IRADIMED CORPORATION does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $23.2 M on assets over the last 3 years. Averaged over those years that is 9.2% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $23.2 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

IRADIMED CORPORATION's P/E is 47.4×, near the low end of its own history: it has been lower only 31% of the time. Its usual P/E (the middle reading) is 49.9×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

Why the multiple is where it is: over the past year earnings per share moved +16.7% while the price moved +5.0%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

IRADIMED CORPORATION's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 27.1%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

IRADIMED CORPORATION earned a ROE of 24% in FY25. That is up from a low of 13% in FY21. Its return on capital used (ROIC) is 42.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 26.8% net margin and 0.77× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 26.8% net margin × 0.77× asset turnover × 1.15× leverage (assets divided by equity) ≈ 23.7% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 51.8% − 9.4% = +42.4 percentage points. The 9.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 51.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 53.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

IRADIMED CORPORATION has total debt of $59.0 K against shareholder equity of $90.1 M as of Mar 2025, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.00 in FY24. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

8.0% of IRADIMED CORPORATION's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For IRADIMED CORPORATION, the Z-score is 51.16. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 51.16 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: IRADIMED CORPORATION is not among the largest members shown in this industry comparison for Medical Devices.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

IRADIMED is the 39th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: PROCEPT BioRobotics Corporation, Avanos Medical, Inc. and Integra LifeSciences Holdings Corporation. Just below it: SI-BONE, Inc., CeriBell, Inc. and QuidelOrtho Corporation.

Medical Devices companies close in size

36. PROCEPT BioRobotics Corporation $1.2 billion
37. Avanos Medical, Inc. $1.2 billion
38. Integra LifeSciences Holdings Corporation $1.2 billion
39. IRADIMED CORPORATION $1.1 billion
40. SI-BONE, Inc. $1.1 billion
41. CeriBell, Inc. $1.1 billion
42. QuidelOrtho Corporation $984 million

All 75 Medical Devices companies, largest first

Companies close in size in other industries

2356. LGI Homes, Inc. $1.1 billion · Residential Construction
2357. Napco Security Technologies, Inc. $1.1 billion · Security & Protection Services
2358. IRADIMED CORPORATION $1.1 billion
2359. Middlesex Water Company $1.1 billion · Utilities - Regulated Water
2360. Willdan Group, Inc. $1.1 billion · Engineering & Construction

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.